Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Mild IPF
NCT05052229Phase 1Recruiting
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Nitric Oxide with Placebo (2 arms). Primary endpoints: Ventilatory efficiency and Inspiratory Neural Drive. Started Apr 2022; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05052229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052229.